Study Metrics
Covariates
27
PICO Comparisons
0
Quality Indicators
Transparency
High
DAG Usage
No
QBA Performed
No
Study Information
| First Author: | Kirschgesner |
| Publication Year: | 2021 |
| DOI: | https://doi.org/10.1002/cpt.2304 |
| Preprint: | No preprint |
Institution & Funding
| Institution Type: | Academic |
| Institutions: | Division of Pharmacoepidemiology and Pharmacoeconomics (Department of Medicine, Brigham and Women's Hospital and Harvard Medical School), Department of Gastroenterology (Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine), Division of Rheumatology, Inflammation, and Immunity (Department of Medicine, Brigham and Women's Hospital and Harvard Medical School) |
| Funding: | Declared: Research institute |
| Funding Institutions: | The investigators conducted the research independently through funding from internal sources of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School. |
Study Context
| Disease: | Crohn's disease |
| Disease Category: | Gastroenterology |
| Data Type: | Other |
| Number of Data Sources: | 3 |
| Geography: | US, France |
| Eligible Sample: | 15007.0 |
| Number of Treatments: | 2 |
Analytical Methods
| Matching Method: | PS Matching |
| Analysis Method: | Log-binomial regression |
| Estimand: | Not defined |
Quality Methods
Directed Acyclic Graph (DAG)
Not Used
Quantitative Bias Analysis (QBA)
Not Performed
Target Trial Information
| Target Trial Name: | SONIC |
| Registration Number: | NCT00094458 |
| Target Trial DOI: | https://doi.org/10.1056/NEJMoa0904492 |
Transparency Indicators
Protocol Registration
Available
Data Sharing
Not Available
Code Sharing
Not Available
Overall Transparency Score:
High Transparency - This study meets good transparency standards.
Conflicts & Funding
| Conflicts of Interest: | Declared: Financial |
| COI Institutions: | Roche, Pfizer, Janssen, Allergan, AbbVie, Merck Sharp & Dohme, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda, Tillots, Abbott, Hospira-Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb. |
| Funding Source: | Declared: Research institute |
| Funding Institutions: | The investigators conducted the research independently through funding from internal sources of the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School. |